Taysha Gene Therapies(TSHA) - 2025 Q2 - Quarterly Results

Exhibit 99.1 Taysha Gene Therapies Reports Second Quarter 2025 Financial Results and Provides Corporate Update Commenced site activation for REVEAL pivotal trial in accordance with previously aligned upon key design elements, following receipt of No Objection Letter (NOL) from Health Canada and feedback from the FDA; patient enrollment anticipated to begin in Q4 2025 High dose and low dose TSHA-102 continue to be generally well tolerated with no treatment-related SAEs or DLTs in the 12 patients treated in P ...